Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011)
Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.
Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PM
Session Title: Leukemia, Myelodysplasia and Transplantation
Location: Arie Crown Theater
Oral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)
Abstract # 122
Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study. S. O'Brien et al.
Date/Time: Friday, June 17, 2011; 9:45 AM
Session 10: Chronic Lymphocytic Leukemia (CLL)
Location: Room A, B, C and Marquee Parco Ciani)
Abstract # 153
Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study. R.H. Advani et al.
Date/Time: Saturday, June 18, 2011; 9:30 AM
Session 14: Signaling Pathways in Lymphoma
Location: Room A
Subscribe to our Free Newsletters!
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...View All